<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042600</url>
  </required_header>
  <id_info>
    <org_study_id>2599</org_study_id>
    <nct_id>NCT01042600</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation</brief_title>
  <official_title>Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ONY</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LMA North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, newborn babies with respiratory distress syndrome (RDS), receiving oxygen via
      nasal CPAP, and needing surfactant treatment will be randomized to standard delivery of
      surfactant via and endotracheal tube airway(inserted after pre-medication for pain), or to
      surfactant delivery via laryngeal mask airway (LMA). The intent is to remove the airways and
      return babies to nasal CPAP, after surfactant is given. The primary outcome measure is the
      rate of failure of initial surfactant therapy. Standardized failure criteria are reached: a)
      early, if the baby is unable to be placed back on CPAP (needs mechanical ventilation) or, b)
      late, if the baby requires retreatment with surfactant within 8 hours or more than 2 doses of
      surfactant.

      The objective of this protocol is to reduce the need for endotracheal intubation and
      mechanical ventilation in preterm neonates with RDS needing rescue surfactant therapy by
      instilling surfactant though an LMA, while achieving comparable efficacy of surfactant
      treatment.

      The hypothesis is that surfactant treatment through an LMA will decrease the proportion of
      babies with RDS who require mechanical ventilation or subsequent intubation, when compared
      with standard surfactant treatment following sedation and endotracheal intubation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory Distress Syndrome (RDS) due to deficiency of lung surfactant is common in preterm
      newborns. Early treatment with surfactant improves oxygenation, reduces the need for
      subsequent mechanical ventilation, decreases the incidence of pulmonary air leaks and chronic
      lung disease and it also reduces mortality in extremely premature newborns. Optimal treatment
      of RDS includes surfactant therapy and avoidance of invasive mechanical ventilation by using
      nasal continuous positive airway pressure (NCPAP). The current standard method of surfactant
      delivery requires tracheal intubation and at least brief positive-pressure ventilation.
      Tracheal intubation causes pain and leads to vagal-mediated physiologic instability in
      neonates; therefore, premedication with morphine and atropine is routinely practiced in our
      setting. However, premedication with morphine often increases respiratory depression,
      requiring sustained mechanical ventilation. The Laryngeal Mask Airway (LMA) is a commercially
      available, less invasive artificial airway that does not need to be inserted into the
      trachea; it is FDA-approved for use in neonates, and preliminary data suggest that it can be
      used for surfactant administration.

      The main objective of this study protocol is reduce the need for endotracheal intubation and
      mechanical ventilation in preterm neonates with mild to moderate RDS needing rescue
      surfactant therapy by instilling surfactant though an LMA. A second objective is to compare
      the efficacy of surfactant administered via LMA versus endotracheal tube (ETT) in decreasing
      the severity of RDS. Additionally, we will evaluate the safety of surfactant administration
      via LMA.

      The primary hypothesis is that surfactant treatment via the LMA approach will decrease the
      proportion of babies with RDS who require mechanical ventilation or subsequent intubation,
      when compared with standard surfactant as administered to the ETT group.

      This randomized controlled trial will include babies with mild-to-moderate RDS, between 4 to
      48 hours of age, with gestational age 29 0/7 to 36 6/7 weeks, treated with NCPAP ≥ 5 cm H2O
      and FiO2 between 0.30 and 0.60 for at least 2 hours to maintain SpO2 88-95%, and informed
      consent. Exclusion criteria are weight &lt; 1000 g, airway anomalies, pulmonary air leaks, and
      craniofacial and cardiothoracic malformations.

      After informed consent is obtained, babies are randomly assigned (from sealed, opaque,
      consecutively numbered envelopes), to the &quot;ETT&quot; or &quot;LMA&quot;. The &quot;ETT&quot; group is managed
      according to our current practice of surfactant therapy (endotracheal intubation following
      premedication with atropine + morphine), whereas the &quot;LMA&quot; group will be pre-medicated with
      atropine before LMA insertion for surfactant administration.

      Both groups will receive Infasurf (3mL/kg) instilled in 2 aliquots via their respective
      airway, followed by PPV for at least 5 minutes. The artificial airway will be removed and the
      patient returned to NCPAP by 15 minutes, if spontaneous respirations are adequate.
      Indications for surfactant re-dosing and mechanical ventilation will be equivalent for both
      groups.

      Babies will continue or initiate assisted ventilation via ETT if any of the following occurs:

        -  Persistent apnea;

        -  Severe retractions;

        -  Inability to wean FiO2 &lt; 60%

      Criteria for re‐dosing with surfactant:

        1. Within 8 hours after first dose of surfactant (early re‐dosing):

             -  FiO2 20% higher than the baseline FiO2, after excluding other obvious causes of
                respiratory insufficiency such as pneumothorax.

           If early re‐dosing of surfactant is needed in patients of either group, the dose will be
           administered via ETT (i.e., LMA patients will be intubated, and will receive the dose of
           surfactant via ETT)

        2. Beyond 8 hours of the first dose of surfactant (late re‐dosing):

             -  FiO2 is ≥ 60%, or;

             -  FiO2is ≥ 30% associated with worsening clinical signs of RDS.

      If late re‐dosing is needed in patients of the LMA group, use of the LMA is permitted for the
      second dose. In the ETT group, all doses are given via the ETT.

      Primary Outcome Measures:

      Rate of failure of early surfactant rescue therapy in the 2 groups, using the following
      criteria to differentiate early from late failure:

        -  Criteria for early failure (within 1 hour):

             1. The need of mechanical ventilation within 1 hour of surfactant therapy.

             2. Use of Narcan to avoid mechanical ventilation after surfactant therapy.

        -  Criteria for late failure (beyond 1 hour):

             1. Sustained FiO2 &gt; 0.60 to maintain target SpO2

             2. Second dose of surfactant within 8 hours after the first dose.

             3. More than 2 doses of surfactant.

      Babies will have FiO2 adjusted to maintain SpO2 88-95%, per current practice. Other aspects
      of weaning ventilatory support will be managed by clinicians' preference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 &gt; 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant).</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Surfactant Doses</measure>
    <time_frame>96 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Assisted Ventilation</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Supplemental Oxygen</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pneumothorax</measure>
    <time_frame>96 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of BPD (O2 Dependence at the Later of 28 Days of Age or 36 Weeks Postmenstrual Age)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications During Insertion of LMA</measure>
    <time_frame>96 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Intubation Episodes Per Patient</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>Endotracheal intubation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laryngeal mask airway</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tube insertion</intervention_name>
    <description>Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
    <arm_group_label>Endotracheal intubation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laryngeal mask airway insertion</intervention_name>
    <description>Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
    <arm_group_label>Laryngeal mask airway</arm_group_label>
    <other_name>LMA North America</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild-to-moderate RDS

          -  Postnatal age 4 to 48 hours

          -  Gestational age 29 0/7 to 36 6/7 weeks

          -  Treated with nasal CPAP ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 hours
             to maintain SpO2 88-95%

          -  Informed consent

        Exclusion Criteria:

          -  Weight &lt; 1000 g

          -  Airway anomalies

          -  Pulmonary air leaks

          -  Craniofacial or cardiothoracic malformations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim M Pinheiro, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Querube Santana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <results_first_submitted>June 16, 2014</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Joaquim M.B. Pinheiro</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Respiratory distress syndrome</keyword>
  <keyword>Surfactant</keyword>
  <keyword>Tracheal intubation</keyword>
  <keyword>Laryngeal mask airway</keyword>
  <keyword>Newborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant excluded and removed from study after randomization due to ineligibility (pre-existing pneumothorax)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Endotracheal Intubation</title>
          <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
        </group>
        <group group_id="P2">
          <title>Laryngeal Mask Airway</title>
          <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Single ineligible patient excluded in the endotracheal intubation group</population>
      <group_list>
        <group group_id="B1">
          <title>Endotracheal Intubation</title>
          <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
        </group>
        <group group_id="B2">
          <title>Laryngeal Mask Airway</title>
          <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gestational age &lt;33 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gestational age &gt;=33 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 &gt; 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant).</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 &gt; 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant).</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Surfactant Doses</title>
        <time_frame>96 hr</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Assisted Ventilation</title>
        <time_frame>2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Supplemental Oxygen</title>
        <time_frame>2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Pneumothorax</title>
        <time_frame>96 hrs</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of BPD (O2 Dependence at the Later of 28 Days of Age or 36 Weeks Postmenstrual Age)</title>
        <time_frame>2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications During Insertion of LMA</title>
        <time_frame>96 hrs</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Intubation Episodes Per Patient</title>
        <time_frame>7 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate</title>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Endotracheal Intubation</title>
          <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
        </group>
        <group group_id="E2">
          <title>Laryngeal Mask Airway</title>
          <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>Pneumothorax after randomization</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joaquim Pinheiro, MD, MPH</name_or_title>
      <organization>Albany Medical Center</organization>
      <phone>518-262-5421</phone>
      <email>pinheij@mail.amc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

